Literature DB >> 19683287

Hyaluronic acid and HYAL-1 in prostate biopsy specimens: predictors of biochemical recurrence.

Christopher S Gomez1, Pablo Gomez, Judith Knapp, Merce Jorda, Mark S Soloway, Vinata B Lokeshwar.   

Abstract

PURPOSE: Molecular markers could aid prostate specific antigen, biopsy Gleason sum and clinical stage to provide accurate information on prostate cancer progression. HYAL-1 hyaluronidase and hyaluronic acid staining in prostatectomy specimens predicts biochemical recurrence. We examined whether hyaluronic acid and HYAL-1 staining in biopsy specimens predicts biochemical recurrence and correlates with staining in matched prostatectomy specimens.
MATERIALS AND METHODS: Biopsy and prostatectomy specimens were obtained from 61 patients with clinically localized prostate cancer from multiple centers, including 23 with (group 1) and 38 without (group 2) biochemical recurrence. Mean followup was 103.1 months. Biotinylated hyaluronic acid binding protein and anti-HYAL-1 antibody were used for hyaluronic acid and HYAL-1 staining, respectively. Staining was graded between 0 and 300 depending on staining intensity and area.
RESULTS: HYAL-1 and hyaluronic acid were expressed in tumor cells and stroma, respectively. In biopsy specimens HYAL-1 and hyaluronic acid expression was higher in group 1 than in group 2 (203.9 and 182.1 vs 48.8 and 87.0, respectively, p <0.0001). On univariate analysis hyaluronic acid, HYAL-1, biopsy Gleason and prostate specific antigen significantly predicted biochemical recurrence (p <0.001). On multivariate analysis only HYAL-1 staining independently predicted recurrence with an accuracy of 81.8% (p <0.001). In prostatectomy specimens only HYAL-1 staining correlated with staining in biopsy specimens (Spearman rho = 0.72, p = 0.0002) and predicted biochemical recurrence.
CONCLUSIONS: To our knowledge this is the first report that HYAL-1 staining in biopsy specimens is an independent predictor of biochemical recurrence. This may be useful when selecting treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19683287      PMCID: PMC2828051          DOI: 10.1016/j.juro.2009.06.070

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  23 in total

Review 1.  Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets.

Authors:  Bora Gurel; Tsuyoshi Iwata; Cheryl M Koh; Srinivasan Yegnasubramanian; William G Nelson; Angelo M De Marzo
Journal:  Adv Anat Pathol       Date:  2008-11       Impact factor: 3.875

2.  Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence.

Authors:  Daniel J Caruso; Adrienne J K Carmack; Vinata B Lokeshwar; Robert C Duncan; Mark S Soloway; Bal L Lokeshwar
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

Review 3.  EAU guidelines on prostate cancer.

Authors:  Axel Heidenreich; Gunnar Aus; Michel Bolla; Steven Joniau; Vsevolod B Matveev; Hans Peter Schmid; Filliberto Zattoni
Journal:  Eur Urol       Date:  2007-09-19       Impact factor: 20.096

Review 4.  Therapeutic options for hormone-refractory prostate cancer in 2007.

Authors:  Boris A Hadaschik; Martin E Gleave
Journal:  Urol Oncol       Date:  2007 Sep-Oct       Impact factor: 3.498

5.  Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing.

Authors:  Alamelu G Bharadwaj; Joy L Kovar; Eileen Loughman; Christian Elowsky; Gregory G Oakley; Melanie A Simpson
Journal:  Am J Pathol       Date:  2009-02-13       Impact factor: 4.307

Review 6.  Hyalurondiase: both a tumor promoter and suppressor.

Authors:  Vinata B Lokeshwar; Marie G Selzer
Journal:  Semin Cancer Biol       Date:  2008-03-26       Impact factor: 15.707

7.  Androgen receptor regulates CD168 expression and signaling in prostate cancer.

Authors:  Shi-Lung Lin; Donald Chang; Angela Chiang; Shao-Yao Ying
Journal:  Carcinogenesis       Date:  2008-01-03       Impact factor: 4.944

Review 8.  Hyaluronan and hyaluronidase in genitourinary tumors.

Authors:  Melanie A Simpson; Vinata B Lokeshwar
Journal:  Front Biosci       Date:  2008-05-01

9.  HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer.

Authors:  Mario W Kramer; Roozbeh Golshani; Axel S Merseburger; Judith Knapp; Alfredo Garcia; Joerg Hennenlotter; Robert C Duncan; Mark S Soloway; Merce Jorda; Marcus A Kuczyk; Arnulf Stenzl; Vinata B Lokeshwar
Journal:  Eur Urol       Date:  2009-03-31       Impact factor: 20.096

Review 10.  Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan.

Authors:  Raija H Tammi; Anne Kultti; Veli-Matti Kosma; Risto Pirinen; Päivi Auvinen; Markku I Tammi
Journal:  Semin Cancer Biol       Date:  2008-03-26       Impact factor: 15.707

View more
  20 in total

1.  Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells.

Authors:  Xinhai Wan; Jie Liu; Jing-Fang Lu; Vassiliki Tzelepi; Jun Yang; Michael W Starbuck; Lixia Diao; Jing Wang; Eleni Efstathiou; Elba S Vazquez; Patricia Troncoso; Sankar N Maity; Nora M Navone
Journal:  Clin Cancer Res       Date:  2012-02-01       Impact factor: 12.531

2.  Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells.

Authors:  Vinata B Lokeshwar; Luis E Lopez; Daniel Munoz; Andrew Chi; Samir P Shirodkar; Soum D Lokeshwar; Diogo O Escudero; Neetika Dhir; Norman Altman
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

3.  Molecular characterization of kidney cancer: association of hyaluronic acid family with histological subtypes and metastasis.

Authors:  Andrew Chi; Samir P Shirodkar; Diogo O Escudero; Obi O Ekwenna; Travis J Yates; Rajinikanth Ayyathurai; Michael Garcia-Roig; Jeffrey C Gahan; Murugesan Manoharan; Vincent G Bird; Vinata B Lokeshwar
Journal:  Cancer       Date:  2011-09-01       Impact factor: 6.860

4.  Hyaluronidase Hyal1 Increases Tumor Cell Proliferation and Motility through Accelerated Vesicle Trafficking.

Authors:  Caitlin O McAtee; Abigail R Berkebile; Christian G Elowsky; Teresa Fangman; Joseph J Barycki; James K Wahl; Oleh Khalimonchuk; Naava Naslavsky; Steve Caplan; Melanie A Simpson
Journal:  J Biol Chem       Date:  2015-04-08       Impact factor: 5.157

5.  Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis.

Authors:  Mario W Kramer; Diogo O Escudero; Soum D Lokeshwar; Roozbeh Golshani; Obi O Ekwenna; Kristell Acosta; Axel S Merseburger; Mark Soloway; Vinata B Lokeshwar
Journal:  Cancer       Date:  2010-10-19       Impact factor: 6.860

Review 6.  Aging-related alterations in the extracellular matrix modulate the microenvironment and influence tumor progression.

Authors:  Cynthia C Sprenger; Stephen R Plymate; May J Reed
Journal:  Int J Cancer       Date:  2010-10-08       Impact factor: 7.396

7.  Significance of elevated levels of collagen type IV and hyaluronic acid in gastric juice and serum in gastric cancer and precancerous lesion.

Authors:  Hai-Ling Ruan; Ru-Tao Hong; Hui-Jun Xie; Nai-Zhong Hu; Jian-Ming Xu; Wei Zhang
Journal:  Dig Dis Sci       Date:  2011-01-25       Impact factor: 3.199

8.  Prostate cancer increases hyaluronan in surrounding nonmalignant stroma, and this response is associated with tumor growth and an unfavorable outcome.

Authors:  Andreas Josefsson; Hani Adamo; Peter Hammarsten; Torvald Granfors; Pär Stattin; Lars Egevad; Anna Engström Laurent; Pernilla Wikström; Anders Bergh
Journal:  Am J Pathol       Date:  2011-08-18       Impact factor: 4.307

9.  Definition of biochemical recurrence after radical prostatectomy does not substantially impact prognostic factor estimates.

Authors:  Angel M Cronin; Guilherme Godoy; Andrew J Vickers
Journal:  J Urol       Date:  2010-01-18       Impact factor: 7.450

Review 10.  Emerging roles for hyaluronidase in cancer metastasis and therapy.

Authors:  Caitlin O McAtee; Joseph J Barycki; Melanie A Simpson
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.